BetterLife Obtains TD-0148A Behavioural Pharmacology Data Confirming its Projected Non-hallucinogenic Property
Retrieved on:
Tuesday, November 16, 2021
National Institutes of Health, University, Degenerative disease, Coronavirus, U.S. News & World Report, UCSD, CSE, Depression, News, Bedsider, Faculty, Immune system, National, Pharmacology, UC, COVID-19, Lists of diseases, Research, UC San Diego School of Medicine, Human, UC San Diego Health, Headache, GLOBE, Psychiatry, Psychedelic drug, University of California, San Diego, Head-twitch response, Mouse, Post-traumatic stress disorder, Patient, LSD, HTR, Hallucination, IND, Lysergic acid diethylamide, Pharmaceutical industry
TD-0148A is a second-generation Lysergic Acid Diethylamide (LSD) derivative molecule that BetterLife believes will mimic the therapeutic potential of LSD without causing psychedelic effects, such as hallucinations.
Key Points:
- TD-0148A is a second-generation Lysergic Acid Diethylamide (LSD) derivative molecule that BetterLife believes will mimic the therapeutic potential of LSD without causing psychedelic effects, such as hallucinations.
- The head-twitch-response (HTR) assay in mice is commonly used to evaluate a compounds hallucinogenic potential in humans.
- Dr. Halberstadts laboratory is one of the leading research groups focusing on the development of automated HTR assessment methods.
- "We are pleased to confirm the projected non-hallucinogenic nature of TD-0148A as part of our behavioural pharmacology studies conducted in collaboration with Dr. Halberstadt and his team.